Security Snapshot

Axsome Therapeutics, Inc. - Common Stock (AXSM) Institutional Ownership

CUSIP: 05464T104

13F Institutional Holders and Ownership History from Q4 2015 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

395

Shares (Excl. Options)

37,608,136

Price

$182.64

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock
Symbol
AXSM on Nasdaq
Shares outstanding
48,932,355
Price per share
$168.74
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
37,608,136
Total reported value
$6,859,673,674
% of total 13F portfolios
0.02%
Share change
-665,030
Value change
+$13,353,330
Number of holders
395
Price from insider filings
$168.74
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • AXSM - Axsome Therapeutics, Inc. - Common Stock is tracked under CUSIP 05464T104.
  • 395 institutions reported positions in Q4 2025.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 395 to 171 between Q4 2025 and Q1 2026.
  • Reported value moved from $6,859,673,674 to $1,546,271,669.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 395 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 05464T104?
CUSIP 05464T104 identifies AXSM - Axsome Therapeutics, Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Axsome Therapeutics, Inc. - Common Stock (AXSM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RTW INVESTMENTS, LP 3.1% -48% $165,312,089 -$153,206,917 1,516,903 -48% RTW Investments, LP 30 Jun 2025

As of 31 Dec 2025, 395 institutional investors reported holding 37,608,136 shares of Axsome Therapeutics, Inc. - Common Stock (AXSM). This represents 77% of the company’s total 48,932,355 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Axsome Therapeutics, Inc. - Common Stock (AXSM) together control 51% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.5% 4,164,818 -0.38% 0.01% $760,662,360
BlackRock, Inc. 8% 3,913,543 +3.2% 0.01% $714,769,493
PRICE T ROWE ASSOCIATES INC /MD/ 3.1% 1,509,870 +46% 0.03% $275,763,000
Invesco Ltd. 2.6% 1,273,494 +29% 0.04% $232,590,944
WELLINGTON MANAGEMENT GROUP LLP 2.5% 1,221,656 -8.5% 0.04% $223,123,252
FMR LLC 2.4% 1,181,622 +27% 0.01% $215,811,444
Deep Track Capital, LP 2.4% 1,150,000 +28% 4.8% $210,036,000
GEODE CAPITAL MANAGEMENT, LLC 2.1% 1,010,249 +1.3% 0.01% $184,544,219
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 2% 989,447 0% 0.27% $180,713,000
STATE STREET CORP 2% 958,150 +1.6% 0.01% $174,996,516
RTW INVESTMENTS, LP 1.8% 888,001 -21% 1.6% $162,184,503
ALETHEA CAPITAL MANAGEMENT, LLC 1.4% 668,710 -0.32% 59% $122,133,194
BANK OF AMERICA CORP /DE/ 1.3% 618,033 +71% 0.01% $112,877,457
EVENTIDE ASSET MANAGEMENT, LLC 1.2% 571,226 -23% 1.6% $104,195,166
D. E. Shaw & Co., Inc. 1.1% 549,113 +85% 0.08% $100,289,998
NORGES BANK 1% 495,456 0.01% $90,490,084
MORGAN STANLEY 1% 491,201 +20% 0.01% $89,713,138
Assenagon Asset Management S.A. 0.96% 467,982 +59% 0.13% $85,472,232
Pictet Asset Management Holding SA 0.89% 436,063 +20% 0.08% $79,642,546
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.82% 402,700 +5.4% 0.01% $73,549,128
NORTHERN TRUST CORP 0.8% 390,431 -4.7% 0.01% $71,308,317
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.75% 367,578 -17% 0.1% $67,134,446
Hood River Capital Management LLC 0.75% 366,176 +1.7% 0.73% $66,878,385
PRINCIPAL FINANCIAL GROUP INC 0.74% 363,114 -1.4% 0.03% $66,319,141
UBS Group AG 0.73% 355,318 +67% 0.01% $64,895,279

Institutional Holders of Axsome Therapeutics, Inc. - Common Stock (AXSM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 9,153,488 $1,546,271,669 +$116,321,677 $169.02 171
2025 Q4 37,608,136 $6,859,673,674 +$13,353,330 $182.64 395
2025 Q3 37,169,613 $4,513,412,476 -$67,590,005 $121.45 352
2025 Q2 37,843,872 $3,950,044,159 +$74,087,650 $104.39 345
2025 Q1 36,999,749 $4,315,367,902 +$55,229,563 $116.63 349
2024 Q4 37,175,235 $3,145,106,906 -$176,513,164 $84.61 290
2024 Q3 38,678,079 $3,475,093,026 -$190,434,872 $89.87 277
2024 Q2 40,712,369 $3,277,256,100 +$165,407,783 $80.50 253
2024 Q1 38,735,398 $3,089,970,732 +$16,979,676 $79.80 254
2023 Q4 38,597,370 $3,071,777,083 +$30,855,225 $79.59 242
2023 Q3 37,879,928 $2,647,367,402 +$88,702,381 $69.89 224
2023 Q2 36,371,724 $2,613,474,662 +$329,094,500 $71.86 227
2023 Q1 31,901,760 $1,967,140,427 +$94,141,631 $61.68 194
2022 Q4 30,053,540 $2,317,913,385 +$384,566,478 $77.13 213
2022 Q3 25,705,114 $1,146,849,855 +$196,048,585 $44.62 180
2022 Q2 21,590,557 $826,608,565 +$90,967,881 $38.30 164
2022 Q1 19,105,701 $787,305,601 +$28,307,048 $41.39 165
2021 Q4 18,632,401 $703,886,639 -$18,569,388 $37.78 161
2021 Q3 19,030,753 $625,717,799 -$187,658,523 $32.96 165
2021 Q2 22,332,926 $1,506,651,537 -$37,805,529 $67.46 172
2021 Q1 22,937,308 $1,299,681,826 -$60,738,349 $56.62 181
2020 Q4 23,974,672 $1,951,921,924 -$4,134,242 $81.47 178
2020 Q3 24,031,769 $1,711,934,785 -$21,143,954 $71.25 171
2020 Q2 24,239,746 $1,992,911,051 +$152,460,166 $82.28 188
2020 Q1 22,843,303 $1,344,655,517 +$45,174,721 $58.83 163
2019 Q4 22,285,098 $2,303,381,131 +$375,930,983 $103.36 168
2019 Q3 18,829,417 $381,131,444 +$8,748,444 $20.24 109
2019 Q2 18,265,403 $470,328,087 +$100,449,906 $25.75 107
2019 Q1 14,726,528 $209,555,043 +$159,660,613 $14.23 64
2018 Q4 3,826,666 $10,790,008 +$478,855 $2.82 35
2018 Q3 3,533,711 $12,193,010 -$1,993,489 $3.45 33
2018 Q2 4,098,087 $13,112,972 -$296,661 $3.20 34
2018 Q1 4,234,235 $10,372,895 -$6,125,369 $2.45 35
2017 Q4 5,822,045 $32,606,017 -$1,045,996 $5.60 33
2017 Q3 6,009,091 $33,278,940 -$2,137,110 $5.55 26
2017 Q2 6,403,943 $35,253,289 -$6,146,767 $5.50 34
2017 Q1 7,754,027 $30,238,589 +$7,294,468 $3.90 47
2016 Q4 6,167,172 $41,627,505 -$969,516 $6.75 41
2016 Q3 6,308,290 $49,689,460 +$4,018,404 $7.88 36
2016 Q2 5,799,374 $43,724,574 +$3,925,477 $7.54 34
2016 Q1 5,260,385 $45,240,000 +$313,024 $8.60 17
2015 Q4 5,216,906 $47,654,000 +$47,654,000 $9.25 11
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .